Herpes Simplex Clinical Trial
— NeemOfficial title:
Effectiveness of TheraNeem Lip Therapy of Common Symptoms of Herpes Simplex Labialis A Prospective Experimental Case Series (n=5)
This study intends to test the efficacy of the TheraNeem Lip Therapy balm for Herpes Simplex. The study will include a total of 5 people.
Status | Completed |
Enrollment | 5 |
Est. completion date | March 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Participant has signs and symptoms of HSV-1 infection of less than 24 hours duration to the Southern California University of Health Sciences investigators 2. Participants ages 18-70 years 3. Confirmation of oral-circumoral herpes lesion will be made by a clinician in the presence of oral-circumoral lesion assumed to be HSV-1 for purposes of study 4. Subjects expressed willingness to comply with protocol 5. Subject will be willing to have the presenting lesion photographed twice 6. Subject sign a written informed consent, HIPPA disclosure, Experimental bill of rights Exclusion Criteria: 1. History of past or present immunosuppressive condition, or currently taking immunosuppressive medication 2. History of adverse effects or allergies to any Neem based product or containing any of the other ingredients TheraNeem Lip Therapy: Organic Coconut Oil, Organic Beeswax, Organic Jojoba Oil, Shea Butter, Sesame Oil, Organic Neem Oil, , Essential Oil of Peppermint, Vitamin E (Tocopherol) 3. Signs of disseminated HSV illness 4. History of use of oral or topical antiviral agents within 10 days of screening and/or at start of study visit 5. Pregnancy or lactation 6. Psychiatric disorder 7. Inability to understand or follow the instructions |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southern California University of Health Science | Whittier | California |
Lead Sponsor | Collaborator |
---|---|
Southern California University of Health Sciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cold Sore Symptom Scale | Baseline and End of Treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05468619 -
Neonatal Phase 1 Valacyclovir Study
|
Phase 1 | |
Withdrawn |
NCT02349828 -
Antiviral Prophylaxis in a Burn Population
|
Phase 2/Phase 3 | |
Recruiting |
NCT01176409 -
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
|
Phase 3 | |
Completed |
NCT04664127 -
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
|
||
Completed |
NCT00448227 -
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
|
Phase 2 | |
Completed |
NCT00000139 -
Herpetic Eye Disease Study (HEDS) II
|
Phase 3 | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT02209324 -
Open-label Study of ASP2151 in Herpes Simplex Patients
|
Phase 3 | |
Completed |
NCT00855309 -
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
|
Phase 3 | |
Completed |
NCT01602562 -
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
|
Phase 3 | |
Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
Completed |
NCT00698893 -
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
|
Phase 1 | |
Active, not recruiting |
NCT05298254 -
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
|
Phase 1/Phase 2 | |
Recruiting |
NCT03178747 -
Tzanck Smear With Methylene Blue Stain for Herpes
|
Phase 3 | |
Completed |
NCT00164424 -
Episodic Acyclovir Therapy for Genital Ulcers
|
Phase 2/Phase 3 | |
Completed |
NCT00161434 -
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
|
Phase 4 | |
Terminated |
NCT04762511 -
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
|
Phase 1 | |
Completed |
NCT00699764 -
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
|
Phase 3 | |
Recruiting |
NCT04065971 -
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
|
Phase 4 | |
Active, not recruiting |
NCT00005663 -
A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
|
Phase 3 |